TG 4010

Drug Profile

TG 4010

Alternative Names: Cancer vaccine - Transgene; MVA-MUC1-IL2; TG-4010

Latest Information Update: 13 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transgene
  • Developer Transgene; University of California, Davis
  • Class Cancer vaccines; Membrane glycoproteins
  • Mechanism of Action Interleukin 12 stimulants; Mucin 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Non-small cell lung cancer
  • Suspended Prostate cancer; Renal cell carcinoma
  • Discontinued Breast cancer

Most Recent Events

  • 11 Sep 2017 The US FDA grants Investigational New Drug clearance to proceed with a phase II trial for Non-small cell lung cancer (Late-stage disease, Combination therapy, First-line therapy) in USA
  • 25 Apr 2017 Transgene in collaboration with Bristol-Myers Squibb plans a phase II trial for Non-small cell lung cancer (Late-stage disease, Combination therapy, First-line therapy, Metastatic disease) in USA (SC) (NCT03353675)
  • 25 Apr 2017 Transgene and Bristol-Myers Squibb enter into a clinical research collaboration agreement to evaluate TG 4010 in combination with nivolumab and standard chemotherapy for Non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top